Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 37, Issue 9, 2006, Pages 851-856

  Ayala, E ^a   Greene, J ^a   Sandin, R ^a   Perkins, J ^a   Field, T ^a   Tate, C ^a   Fields, K K ^b   Goldstein, S ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allogeneic BMT; CMV infection; Pre emptive; Valganciclovir

Indexed keywords

ACICLOVIR; BUSULFAN; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; HEMOGLOBIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HUMAN; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OUTPATIENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT FAILURE; WHOLE BODY RADIATION;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 33646030301     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705341     Document Type: Article

References (28)

1. Meyers JD, Fluornoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation. A review of ten years experience. Rev Infect Dis 1982; 4: 1119-1132.
2. Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. Recommendations of CDC, the Infectious Disease Society of America and the American Society of Blood and Marrow Transplantation. Biol blood Marrow Transplant 2000; 6: 659-713.
3. Boeckh M, Nichols WG, Papanicolaou G, Rubn R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558.
4. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lonnqvist B et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplantation recipients. Transplantation 1998; 66: 1330-1334.
5. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
6. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985.
7. Martino R, Rovira M, Carreras E, Solano C, Jorge S, De La Rubia J et al. Severe infections after allogeneic peripheral blood stem cell transplantation: A matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica 2001; 86: 1075-1086.
8. Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Schrum J et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Hematol 2001; 113: 1060-1071.
9. Bacigalupo A, Mordini N, Pitto A, Piaggio G, Podesta M, Benvenuto F et al. Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: Severe immunodeficiency and related complications. Br J Haematol 1997; 98: 760-766.
10. Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek MR. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 1997; 24: 901-907.
11. Zaia JA. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 633-638.
12. Ljungman P. Prevention and treatment of viral infections in stem cell transplant recipients. Br J Haematol 2002; 118: 44-57.
13. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
14. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Internal Med 1993; 118: 173-178.
15. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Internal Med 1993; 118: 179-184.
16. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 80: 4063-4071.
17. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324: 1005-1011.
18. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-1607.
19. Cvetkovic RS, Wellington K. Valganciclovir: A review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65: 859-878.
20. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-1126.
21. Crowder L, Ruge D, Johnson J. Use of the Digene Hybrid Capture CMV Signal Amplification Assay ver. 2.0 (HC) in a cancer hospital helps modify ganciclovir use for cytomegalovirus from a prophylactic to a preemptive approach. Poster Session #126/C, Abstract C-138, American Society for Microbiology General Meeting, Orlando, FL, May 2001.
22. Schirm J, Kooistra A, van Son WJ, van der Bij W, Verschuuren E, Sprenge HG et al. Comparison of the Murex Hybrid Capture CMV DNA (v2.0) assay and the pp65 antigenemia test for the detection and quantitation of CMV in blood samples from immunocompromised patients. J Clin Virol 1999; 14: 153-165.
23. Hebart H, Wuchter P, Loeffler J, Gscheidle B, Hamprecht K, Sinzger C et al. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant. Bone Marrow Transplant 2001; 28: 213-218.
24. Weinberg A, Schissel D, Giller R. Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients. J Clin Microbiol 2002; 40: 4203-4206.
25. Ljungman P, Griffith P. Definitions of Cytomegalovirus infection and disease. In: Michelson S, Plotkin S (eds). Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Elsevier Science Publishers BV: Amsterdam, 1993.
26. Leather HL, Meyer CL, Wingard JR. Oral (PO) valganciclovir (VGC) for preemptive therapy of cytomegalovirus (CMV) antigenemia (AG) in hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 2003; 9: 238.
27. Einsele H. Preemptive therapy with IV ganciclovir vs valganciclovir: PK and preliminary safety and efficacy data. Oral presentation in CMV in Stem Cell Transplantation: New insights and options. Symposium presented at the Tandem Transplantation Meetings, Orlando, Florida, 2004.
28. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Randomized multicenter trial of foscarnet vs ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.